Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia
H. Lee Moffitt Cancer Center and Research Institute
H. Lee Moffitt Cancer Center and Research Institute
Incyte Corporation
NextCure, Inc.
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
CRISPR Therapeutics
Incyte Corporation
M.D. Anderson Cancer Center
Bristol-Myers Squibb
OHSU Knight Cancer Institute
Scripps Translational Science Institute
Washington University School of Medicine
Celgene
M.D. Anderson Cancer Center
Thomas Jefferson University
Amgen
Thomas Jefferson University
Celgene
Ono Pharmaceutical Co. Ltd
Amgen
Therapeutic Advances in Childhood Leukemia Consortium
Intellia Therapeutics
M.D. Anderson Cancer Center
Bellicum Pharmaceuticals
Eastern Cooperative Oncology Group
Albert Einstein College of Medicine
Northwell Health
Bristol-Myers Squibb
OHSU Knight Cancer Institute
Eli Lilly and Company
Molecular Templates, Inc.
University of Florida
Medical College of Wisconsin
Sanofi
National Institutes of Health Clinical Center (CC)
Sanofi
Brown University
Pfizer
Takeda
Bristol-Myers Squibb
Spectrum Pharmaceuticals, Inc
Novartis
Novartis
M.D. Anderson Cancer Center
PrECOG, LLC.
Therapeutic Advances in Childhood Leukemia Consortium
Therapeutic Advances in Childhood Leukemia Consortium
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
University of California, San Diego